WO2000047762A3 - Enriched central nervous system cell populations - Google Patents

Enriched central nervous system cell populations Download PDF

Info

Publication number
WO2000047762A3
WO2000047762A3 PCT/US2000/003592 US0003592W WO0047762A3 WO 2000047762 A3 WO2000047762 A3 WO 2000047762A3 US 0003592 W US0003592 W US 0003592W WO 0047762 A3 WO0047762 A3 WO 0047762A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell populations
nervous system
central nervous
system cell
enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/003592
Other languages
French (fr)
Other versions
WO2000047762A9 (en
WO2000047762A2 (en
Inventor
David W Buck
Nobuko Uchida
Irving Weissman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stem Cells Inc
Original Assignee
Stem Cells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/422,844 external-priority patent/US6468794B1/en
Priority to DK00911779T priority Critical patent/DK1144671T3/en
Priority to CA2361249A priority patent/CA2361249C/en
Priority to AU33618/00A priority patent/AU780256B2/en
Priority to JP2000598656A priority patent/JP5007003B2/en
Priority to EP00911779A priority patent/EP1144671B1/en
Application filed by Stem Cells Inc filed Critical Stem Cells Inc
Priority to DE60037007T priority patent/DE60037007T2/en
Publication of WO2000047762A2 publication Critical patent/WO2000047762A2/en
Publication of WO2000047762A3 publication Critical patent/WO2000047762A3/en
Anticipated expiration legal-status Critical
Priority to US09/890,469 priority patent/US7037719B1/en
Publication of WO2000047762A9 publication Critical patent/WO2000047762A9/en
Priority to AU2005202534A priority patent/AU2005202534B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Enriched neural stem and progenitor cell populations, and methods for identifying, isolating and enriching for neural stem cells using reagent that bind to cell surface markers, are provided.
PCT/US2000/003592 1999-02-12 2000-02-11 Enriched central nervous system cell populations Ceased WO2000047762A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2361249A CA2361249C (en) 1999-02-12 2000-02-11 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
DE60037007T DE60037007T2 (en) 1999-02-12 2000-02-11 ENRICHED CENTRAL NERVE SYSTEM CELL POPULATIONS
AU33618/00A AU780256B2 (en) 1999-02-12 2000-02-11 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
JP2000598656A JP5007003B2 (en) 1999-02-12 2000-02-11 Enriched populations of central nervous system stem and progenitor cells and methods for identifying, isolating and enriching such populations
EP00911779A EP1144671B1 (en) 1999-02-12 2000-02-11 Enriched central nervous system cell populations
DK00911779T DK1144671T3 (en) 1999-02-12 2000-02-11 Enriched central nervous system cell populations
US09/890,469 US7037719B1 (en) 1999-02-12 2001-11-03 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
AU2005202534A AU2005202534B2 (en) 1999-02-12 2005-06-10 Enriched Central Nervous System Stem Cell and Progenitor Cell Populations, and Methods for Indentifying, Isolating and Enriching for Such Populations

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11972599P 1999-02-12 1999-02-12
US09/422,844 US6468794B1 (en) 1999-02-12 1999-10-21 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US16840799P 1999-12-01 1999-12-01
US09/422,844 1999-12-01
US60/168,407 1999-12-01
US60/119,725 1999-12-01

Publications (3)

Publication Number Publication Date
WO2000047762A2 WO2000047762A2 (en) 2000-08-17
WO2000047762A3 true WO2000047762A3 (en) 2000-12-21
WO2000047762A9 WO2000047762A9 (en) 2002-04-11

Family

ID=46844555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003592 Ceased WO2000047762A2 (en) 1999-02-12 2000-02-11 Enriched central nervous system cell populations

Country Status (10)

Country Link
US (1) US20070238171A1 (en)
EP (2) EP1900811B1 (en)
JP (2) JP5007003B2 (en)
AT (2) ATE377652T1 (en)
AU (2) AU780256B2 (en)
CA (1) CA2361249C (en)
DE (2) DE60044655D1 (en)
DK (2) DK1900811T3 (en)
ES (2) ES2351170T3 (en)
WO (1) WO2000047762A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
DE60044655D1 (en) * 1999-02-12 2010-08-19 Stemcells California Inc Enriched cell populations of the central nervous system
US20050042749A1 (en) 2001-05-16 2005-02-24 Carpenter Melissa K. Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
US7250294B2 (en) 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
EP1287116A2 (en) 2000-05-17 2003-03-05 Geron Corporation Neural progenitor cell populations
WO2002097069A1 (en) * 2001-06-01 2002-12-05 University Of Sydney Purification of lineage-specific cells and uses therefor
AUPR540301A0 (en) * 2001-06-01 2001-06-28 Walter And Eliza Hall Institute Of Medical Research, The A method of purification of cells
ATE371018T1 (en) 2001-06-22 2007-09-15 Stemcells Inc LE CELLS (LIVER ENGRAFTING CELLS), ASSAY AND USES THEREOF
US7381561B2 (en) 2002-08-27 2008-06-03 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
JP4481706B2 (en) * 2004-03-31 2010-06-16 独立行政法人科学技術振興機構 Cerebral infarction disease model mouse
WO2008064408A1 (en) * 2006-11-27 2008-06-05 The University Of Queensland Generation of enriched populations of neural progenitor cells and their progeny
DK2114167T3 (en) * 2007-01-16 2018-09-17 Univ Rochester NON-HUMAN ANIMALS WITH HUMAN GLIAKIMARY BRAIN
JP5035928B2 (en) * 2009-12-15 2012-09-26 独立行政法人産業技術総合研究所 Screening method for human neural stem cells
JP4997613B2 (en) * 2009-12-15 2012-08-08 独立行政法人産業技術総合研究所 Monoclonal antibody selective for human neural stem cells and screening method using the same
JP6090735B2 (en) * 2012-03-02 2017-03-08 国立大学法人山口大学 Serum-free medium for culturing digestive cancer stem cells, and method for proliferating digestive cancer stem cells using the same
ES2927175T3 (en) 2013-02-12 2022-11-03 Reneuron Ltd Microparticle production method
TWI482782B (en) * 2013-05-31 2015-05-01 Univ Nat Chiao Tung Antibody-conjugated double emulsion core-shell nano structure
EP4526433A4 (en) * 2022-05-20 2026-05-06 Univ Leland Stanford Junior METHOD FOR ISSUING NEURAL STEM AND PRECOURSE CELLS FROM THE DEVELOPING HUMAN BRAIN

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002593A1 (en) * 1992-07-27 1994-02-03 California Institute Of Technology Mammalian multipotent neural stem cells
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US5843633A (en) * 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
WO2000012683A2 (en) * 1998-08-31 2000-03-09 New York University Stem cells bearing an fgf receptor on the cell surface

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
IT1264903B1 (en) 1993-06-30 1996-10-17 Sniaricerche S C P A METAL-ORGANIC LIQUID CRYSTALS IN A POLYMERIC MATRIX
CA2294737A1 (en) * 1997-07-04 1999-01-14 University Of Utah Research Foundation Neuron-restricted precursor cells
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6852533B1 (en) * 1998-01-23 2005-02-08 Cornell Research Foundation, Inc. Purified populations of stem cells
US6451306B1 (en) * 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
DE60044655D1 (en) * 1999-02-12 2010-08-19 Stemcells California Inc Enriched cell populations of the central nervous system
US7037719B1 (en) * 1999-02-12 2006-05-02 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US6468794B1 (en) * 1999-02-12 2002-10-22 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US7105150B2 (en) * 1999-02-12 2006-09-12 Stemcells California, Inc. In vivo screening methods using enriched neural stem cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002593A1 (en) * 1992-07-27 1994-02-03 California Institute Of Technology Mammalian multipotent neural stem cells
US5843633A (en) * 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
WO2000012683A2 (en) * 1998-08-31 2000-03-09 New York University Stem cells bearing an fgf receptor on the cell surface

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CORBEIL DENIS; ROEPER KATJA; HANNAH MATTHEW J; HELLWIG ANDREA; HUTTNER WIELAND B: "Selective localization of the polytopic membrane protein prominin in microvilli of epithelial cells - A combination of apical sorting and retention in plasma membrane protrusions", JOURNAL OF CELL SCIENCE, vol. 112, April 1999 (1999-04-01), pages 1023 - 1033, XP000925392 *
D CORBEIL, K RÖPER, A WEIGMANN, W B HUTTNER: "AC133 Hematopoietic Stem Cell Antigen: Human Homologue of Mouse Kidney Prominin or Distinct Member of a Novel Protein Family?", BLOOD, vol. 91, no. 7, 1998, pages 2625 - 2626, XP002143049 *
S MIRAGLIA, W GODGREY, D BUCK: "A Response to AC133 Hematopoietic Stem Cell Antigen: Human Homologue of Mouse Kidney Prominin or Distinct Member of a Novel Protein Family?", BLOOD, vol. 91, no. 11, 1998, pages 4390 - 4391, XP002143048 *
UCHIDA N; HE D; REITSMA M J; MASEK M; WEISSMAN I; GAGE F; BUCK D: "Direct isolation of human neural stem cells from fetal brain by cell sorting", SOCIETY FOR NEUROSCIENCE ABSTRACTS (29TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE.; MIAMI BEACH, FLORIDA, USA; OCTOBER 23-28, 1999), vol. 25, no. 1-2, 1999, pages 1767, XP000925362 *
WEIGMANN ANJA; CORBEIL DENIS; HELLWIG ANDREA; HUTTNER WIELAND B: "Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 94, 11 November 1997 (1997-11-11), pages 12425 - 12430, XP002143047 *

Also Published As

Publication number Publication date
DE60037007T2 (en) 2008-08-21
ATE473273T1 (en) 2010-07-15
DE60044655D1 (en) 2010-08-19
EP1144671A2 (en) 2001-10-17
JP5007003B2 (en) 2012-08-22
WO2000047762A9 (en) 2002-04-11
ES2351170T3 (en) 2011-02-01
ES2295012T3 (en) 2008-04-16
CA2361249C (en) 2011-05-10
EP1144671B1 (en) 2007-11-07
AU3361800A (en) 2000-08-29
DK1900811T3 (en) 2010-10-25
JP2010252808A (en) 2010-11-11
US20070238171A1 (en) 2007-10-11
EP1900811B1 (en) 2010-07-07
EP1900811A1 (en) 2008-03-19
DK1144671T3 (en) 2008-03-17
CA2361249A1 (en) 2000-08-17
AU2005202534A1 (en) 2005-07-07
WO2000047762A2 (en) 2000-08-17
AU780256B2 (en) 2005-03-10
AU2005202534B2 (en) 2008-05-08
ATE377652T1 (en) 2007-11-15
DE60037007D1 (en) 2007-12-20
JP2002536023A (en) 2002-10-29

Similar Documents

Publication Publication Date Title
WO2005021728A3 (en) Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations
WO2004020597A3 (en) Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
ATE377652T1 (en) ENRICHED CENTRAL NERVOUS SYSTEM CELL POPULATIONS
WO2005116073A3 (en) Pdx1 expressing endoderm
AU2001274624A1 (en) Cell fraction containing cells capable of differentiating into nervous system cells
AU2154200A (en) Low oxygen culturing of central nervous system progenitor cells
ATE414783T1 (en) METHOD FOR ISOLATION OF STEM CELLS
WO2007051038A3 (en) Pdx1-expressing dorsal and ventral foregut endoderm
SG149061A1 (en) Definitive endoderm
ATE514772T1 (en) MULTIPOTENT ADULT STEM CELLS AND METHOD FOR ISOLATION THEREOF
WO2003087314A3 (en) Method for isolating and measuring proliferation of long-term label retaining cells and stem cells
AU6380001A (en) Porous ferro- or ferrimagnetic glass particles for isolating molecules
WO2001069244A3 (en) Method for labeling individual cells
AU2002348563A1 (en) Nucleic acid enrichment
AU2002306763A1 (en) Methods for identifying and purifying smooth muscle progenitor cells
WO2002037944A3 (en) Multiplexed cell analysis system
EP1122671A3 (en) System for secure distribution and playback of digital data
WO2004009758A3 (en) Embryonic stem cell markers and uses thereof
EP2088206A3 (en) Induction of the mitochondrial permeability transition
WO1999029279A3 (en) Long-term survival and regeneration of central nervous system neurons
WO2005001042A3 (en) Smooth muscle progenitor cells
WO1999025734A3 (en) Th2 CELL DEPLETION; COMPOSITIONS; METHODS
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
WO2005054445A8 (en) A method for isolating a self-renewing, multipotent slow-cycling cell
WO2004005926A3 (en) 5t4 antigen expression as a marker for stem cell differentiation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2361249

Country of ref document: CA

Ref country code: CA

Ref document number: 2361249

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 33618/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 598656

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000911779

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000911779

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09890469

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWG Wipo information: grant in national office

Ref document number: 33618/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000911779

Country of ref document: EP